Anti-obesity pharmacotherapy in adults with chronic kidney disease

被引：5
作者：
Taber-Hight, Elizabeth [1 ]
Gilmore, Ashley [1 ]
Friedman, Allon N. [1 ]
机构：
[1] Indiana Univ Sch Med, Dept Med, 550 Univ Blvd,Suite 6100, Indianapolis, IN 46202 USA
来源：
KIDNEY INTERNATIONAL | 2024年 / 105卷 / 02期
关键词：
KEYWORDS: chronic kidney disease; glucagon like peptide-1; inflammation; obesity; oxidative stress; weight loss; LIFE-STYLE INTERVENTION; BODY-MASS INDEX; WEIGHT-LOSS; BARIATRIC SURGERY; RECEPTOR AGONIST; BLOOD-PRESSURE; CONTROLLED-TRIAL; OBESE SUBJECTS; FATTY KIDNEY; ORLISTAT;
D O I：
10.1016/j.kint.2023.10.014
中图分类号：
R5 [内科学]; R69 [泌尿科学（泌尿生殖系疾病）];
学科分类号：
1002 ; 100201 ;
摘要：
Obesity is a leading risk factor for the development and progression of kidney disease and a major barrier to optimal management of patients with chronic kidney disease. While in the past anti-obesity drugs offered only modest weight loss efficacy in exchange for various safety and tolerability risks, a wave of safer, more tolerable, and more effective treatment options is transforming the management of obesity. This review evaluates current and future pharmacologic anti-obesity therapy in adults through a kidney-oriented lens. It also explores the goals of anti-obesity treatment, describes the underlying putative mechanisms of action, and raises important scientific questions that deserve further exploration in people with chronic kidney disease.
引用
收藏
页码：269 / 280
页数：12
相关论文
共 142 条
[1]  
Accessdata Fda, Adipex-p
[2]   Mechanisms underlying current and future anti-obesity drugs [J].
Adan, Roger A. H. .
TRENDS IN NEUROSCIENCES, 2013, 36 (02) :133-140
[3]   Health Effects of Overweight and Obesity in 195 Countries over 25 Years [J].
Afshin, Ashkan ;
Forouzanfar, Mohammad H. ;
Reitsma, Marissa B. ;
Sur, Patrick ;
Estep, Kara ;
Lee, Alex ;
Marczak, Laurie ;
Mokdad, Ali H. ;
Moradi-Lakeh, Maziar ;
Naghavi, Mohsen ;
Salama, Joseph S. ;
Vos, Theo ;
Abate, Kalkidan H. ;
Abbafati, Cristiana ;
Ahmed, Muktar B. ;
Al-Aly, Ziyad ;
Alkerwi, Ala'a ;
Al-Raddadi, Rajaa ;
Amare, Azmeraw T. ;
Amberbir, Alemayehu ;
Amegah, Adeladza K. ;
Amini, Erfan ;
Amrock, Stephen M. ;
Anjana, Ranjit M. ;
Arnlov, Johan ;
Asayesh, Hamid ;
Banerjee, Amitava ;
Barac, Aleksandra ;
Baye, Estifanos ;
Bennett, Derrick A. ;
Beyene, Addisu S. ;
Biadgilign, Sibhatu ;
Biryukov, Stan ;
Bjertness, Espen ;
Boneya, Dube J. ;
Campos-Nonato, Ismael ;
Carrero, Juan J. ;
Cecilio, Pedro ;
Cercy, Kelly ;
Ciobanu, Liliana G. ;
Cornaby, Leslie ;
Damtew, Solomon A. ;
Dandona, Lalit ;
Dandona, Rakhi ;
Dharmaratne, Samath D. ;
Duncan, Bruce B. ;
Eshrati, Babak ;
Esteghamati, Alireza ;
Feigin, Valery L. ;
Fernandes, Joao C. .
NEW ENGLAND JOURNAL OF MEDICINE, 2017, 377 (01) :13-27
[4]   Controlled-Release Phentermine/Topiramate in Severely Obese Adults: A Randomized Controlled Trial (EQUIP) [J].
Allison, David B. ;
Gadde, Kishore M. ;
Garvey, William Timothy ;
Peterson, Craig A. ;
Schwiers, Michael L. ;
Najarian, Thomas ;
Tam, Peter Y. ;
Troupin, Barbara ;
Day, Wesley W. .
OBESITY, 2012, 20 (02) :330-342
[5]   Descriptive analysis of reported adverse events associated with anti-obesity medications using FDA Adverse Event Reporting System (FAERS) databases 2013-2020 [J].
Alsuhibani, Abdulrahman ;
Alrasheed, Marwan ;
Gari, Musaab ;
Hincapie, Ana L. ;
Guo, Jeff Jianfei .
INTERNATIONAL JOURNAL OF CLINICAL PHARMACY, 2022, 44 (01) :172-179
[6]   Do attributes of persons with chronic kidney disease differ in low-income and middle-income countries compared with high-income countries? Evidence from population-based data in six countries [J].
Anand, Shuchi ;
Zheng, Yuanchao ;
Montez-Rath, Maria E. ;
Wei, Wang Jin ;
Perico, Norberto ;
Carminati, Sergio ;
Narayan, K. M. Venkat ;
Tandon, Nikhil ;
Mohan, Viswanathan ;
Jha, Vivekanand ;
Zhang, Luxia ;
Remuzzi, Giuseppe ;
Prabahkaran, Dorairaj ;
Chertow, Glenn M. .
BMJ GLOBAL HEALTH, 2017, 2 (04)
[7]   Efficacy and safety of once-daily oral semaglutide 25 mg and 50 mg compared with 14 mg in adults with type 2 diabetes (PIONEER PLUS): a multicentre, randomised, phase 3b trial [J].
Aroda, Vanita R. ;
Aberle, Jens ;
Bardtrum, Lars ;
Christiansen, Erik ;
Knop, Filip K. ;
Gabery, Sanaz ;
Pedersen, Sue ;
Buse, John B. .
LANCET, 2023, 402 (10403) :693-704
[8]   Medicare Part D Coverage of Antiobesity Medications - Challenges and Uncertainty Ahead [J].
Baig, Khrysta ;
Dusetzina, Stacie B. ;
Kim, David D. ;
Leech, Ashley A. .
NEW ENGLAND JOURNAL OF MEDICINE, 2023, 388 (11) :961-963
[9]  
Barbaro Daniele, 2002, Endocr Pract, V8, P124
[10]   Does orlistat cause acute kidney injury? [J].
Beyea, Michael M. ;
Garg, Amit X. ;
Weir, Matthew A. .
THERAPEUTIC ADVANCES IN DRUG SAFETY, 2012, 3 (02) :53-57
12345678910